Objective        To study the expression of β-tubulin-Ⅲ (TUBB3) and topoisomerase II alpha (TOP2A) in patients with advanced breast cancer breast and its relationship with clinical and pathological features of the patients

and analyze the relationship of TUBB3 and TOP2A expression with paclitaxel and anthracycline drug therapeutic effect.       Methods      Sixty patients with advanced breast cancer were selected to detect TUBB3 and TOP2A mRNA expression with liquid-phase chip method

and the TUBB3 and TOP2A mRNA expression levels in the patients with different pathological features was compared. The patients were administered with (docetaxel+pirarubicin+ifosfamide)/(paclitaxel+epirubicin+cyclophosphamide) (PAC/PEC) for 4 weeks. The therapeutic effect was evaluated

and its correlation with TUBB3 and TOP2A mRNA expressions was analyzed.       Results       TUBB3 mRNA levels in the breast cancer patients with different histological grades had statistically significant difference (P0.05). The correlation of TOP2A mRNA expression with age

menopause

histological grade

lymph node metastasis

ER expression

PR expression

and HER-2 expression was not significant (P0.05). The remission rate (57.14%) in the patients with low expression of TUBB3 mRNA was significantly higher than that (14.71%) in the patients with high expression (chi square=5.299

P0.05). The total efficiencies (92.86% and 83.33%) of the patients with low and median expressions of TUBB3 mRNA were significantly higher than that (52.94%) of the patients with high expression (chi square=10.533

4.190

P0.05). The total efficiency (93.55%) of the patients with high expression of TOP2A mRNA was significantly higher than that (69.23%) of the patients with low expression (chi square=3.967

P0.05).       Conclusion       TUBB3 mRNA expression is correlated with the histological grading of breast cancer

and PAC/PEC shows good therapeutic effect in the patients with low TUBB3 expression and high TOP2A expression.